Aspen sells thrombosis drug unit to Mylan

Drugmaker Aspen Pharmacare said on Tuesday it had sold its European thrombosis business to US pharmaceutical company Mylan for almost 642 million euros ($758.65 million).

“The proceeds from the transaction will be used to reduce the group’s debt,” Aspen said in a statement, adding that Mylan will pay 263.2 million euros on completion of the deal and the balance in June 2021.

Read the sens announcement here.